17 results about "Lysophospholipids" patented technology

The invention discloses a phospholipase A1 mutant and application thereof. According to the invention, PLA1 is modified to obtain a PLA1 mutant, compared with wild PLA1, the PLA1 mutant has the advantages that the optimum temperature is kept unchanged, the PLA1 mutant has higher phospholipase A1 activity at 40-50 DEG C, the optimum pH is changed from 3 to 8, and the PLA1 mutant keeps high phospholipase activity at the pH of 3-9 and is higher than the phospholipase activity of the PLA1 wild type under the optimum condition; the pH (Potential of Hydrogen) adaptability range of the PLA1 is widened. Therefore, the PLA1 mutant disclosed by the invention has a better application prospect, better meets the requirement on enzyme performance in phospholipid processing, can be used for degumming grease and producing lysophosphatide, and is applied to the fields of biology, food, medicine, beauty, agriculture, industry and the like.

To provide an industrially usable novel production method regarding type β lysophosphatidic acid, and a novel application of type β lysophosphatidic acid.SOLUTION: A production method including the following processes (1) to (3) is used. Because type β lysophosphatidic acid obtained by the production method has various physiological activity, it can be preferably used for a cosmetic or an external preparation for skin. (1) a process of allowing phospholipase A2 to work for lecithin containing phosphatidylcholine in the water or in a mixed solution of water and organic solvent; (2) a process of allowing phospholipase D to work for a product obtained in the process (1) in the water or in a mixed solution of water and organic solvent; and (3) a process of hydrolyzing a product obtained in the process (2) under an acidic condition in the water or in a mixed solution of water and organic solvent.SELECTED DRAWING: None

The present disclosure relates to engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperones derived from apolipoprotein M (ApoM)-Fc fusion proteins with extended half-life in vivo. The disclosed ApoM-Fc fusion proteins provide a safe, highly efficient and effective way of delivering S1P to endothelial cells and all tissues of the body.

The disclosure provides the structure of an MFSD2A-SYNC2 complex together with functional data that revealed important molecular aspects of MFSD2A transport cycle, receptor-mediated cell-cell fusion, and pharmacology and resulted in the identification of two novel allosteric modulators of MFSD2A, which are two soluble fragments of SYNC2, namely SYNC2su-co and SYNC2su-co-2, representing first-in-class molecules to inhibit MFSD2A LPCs uptake and increase transcytosis rate.

There is provided a feed additive composition. The feed additive composition includes one or more selected from beta-glucan and lysophospholipid, and erythritol. One or more selected from 60 to 100 parts by weight of the beta-glucan and 5 to 10 parts by weight of the lysophospholipid are contained with respect to 100 parts by weight of the erythritol. The erythritol comes from a culture medium of a strain producing erythritol.

The present disclosure relates to a method for producing a lysophospholipid-containing composition in which a phospholipid is decomposed by phospholipase A.

The invention discloses a perovskite precursor solution, a perovskite thin film and application thereof, and belongs to the technical field of solar cells. The perovskite precursor solution comprises a perovskite structure substance raw material, a surfactant and a solvent, the perovskite structure substance raw material has an ABX3 structure, the surfactant is lysophosphatide amphiphilic molecules, and the use amount of the surfactant is 0.001%-20% of the molar weight of B-site ions in the perovskite structure substance raw material. According to the invention, the dual-functional surfactant is introduced into the perovskite precursor solution, so that a high-uniformity and high-density perovskite light absorption layer can be obtained on the substrate, and the photoelectric conversion efficiency of the perovskite solar cell is remarkably improved.

The present invention provides an oil-in-water emulsion cosmetic having excellent usability, such as non-stickiness, elasticity, and penetration, which can stably incorporate an emulsion that is solid at 25°C and has an IOB value of 0.2 to 0.8 into a liquid oil-in-water emulsion cosmetic. The present invention is an oil-in-water emulsion cosmetic containing (A) an emulsion that is solid at 25°C and has an IOB value of 0.2 to 0.8, (B) an emulsion that is liquid at 25°C and has an HSP distance Ra of 7.0 or less from component (A), (C) one or more selected from the group consisting of phospholipids and lysophospholipids, and (D) one or more selected from ethanol and polyhydric alcohols having an IOB value of 1.5 to 5, and having an average particle size of emulsion droplets of 400 nm or less.

The invention provides an oil-soluble plant compound and a preparation method thereof, and belongs to the field of medical, dental or cosmetic preparations. The composition consists of chrysanthellum indicum, ligusticum wallichii, frankincense, exocarpium citri grandis essential oil and a soybean-radix puerariae co-fermentation product. The technical core is as follows: soybean and radix puerariae are subjected to synergistic liquid fermentation by using aspergillus oryzae, lysophosphatide, soybean polypeptide and puerarin aglycone are generated in situ through biotransformation, and an endogenous self-emulsifying carrier is constructed. According to the process, the transdermal penetration promoting capacity of active components is remarkably enhanced by utilizing the regulating effect of ligusticum wallichii oil on cuticle lipid arrangement and combining a micro-micelle structure formed by a co-fermentation system. Nanoscale self-solubilization of four essential oil matrixes in a fermentation substrate is achieved, the skin barrier repair and inflammation inhibition effects are enhanced through multi-target cooperation, and the bioavailability, penetration depth and safety of active ingredients are greatly improved.

The phospholipid composition containing a surfactant according to the present application contains a lysophospholipid and a sulfosuccinate-based surfactant, whereby the lysophospholipid as an effective ingredient can be well dispersed even in an aqueous solution, and the effective ingredient is not easily decomposed even if stored for a long time, and its efficacy can be maintained for a long time. Therefore, the phospholipid composition of the present application can inhibit the decomposition of the lysophospholipid as an effective ingredient, and thus the product can be stored for a long time, and thus, compared with the existing agricultural chemical composition having a short circulation period, it can be more easily used commercially.

This invention provides an oil-in-water emulsion cosmetic that can stably incorporate an oil with an IOB value of 0.2 to 0.8 and which is solid at 25°C into a liquid oil-in-water emulsion cosmetic, providing an excellent user experience with no stickiness, tightness, or penetration. This invention is an oil-in-water emulsion cosmetic containing: (A) an oil with an IOB value of 0.2 to 0.8 and which is solid at 25°C; (B) an oil with an HSP distance Ra of less than 7.0 from component (A) and which is liquid at 25°C; (C) one or more components selected from the group consisting of phospholipids and lysophospholipids; and (D) one or more components selected from ethanol and polyols with an IOB value of 1.5 to 5, wherein the average particle size of the emulsion droplets is less than 400 nm.

This invention discloses a phospholipase A1 mutant and its applications, belonging to the fields of biotechnology and enzyme engineering. The mutant is obtained by site-directed mutagenesis of phospholipase A1-MFI, selected from any one of W166V, W166L, A116F, or L170H. Enzymatic property tests show that the mutant exhibits high hydrolytic activity under conditions of pH 8-10 and temperature 20-35℃. Compared with the wild type, the mutant shows significantly improved specific enzyme activity, PC hydrolysis rate, and LPC yield. This invention also discloses the nucleotide molecule encoding the mutant, the recombinant vector, the host cell, and its application in the preparation of lysophospholipids from hydrolyzed phospholipids. The phospholipase A1 mutant of this invention exhibits excellent catalytic performance and is suitable for use in food, pharmaceutical, and feed industries.

The present invention addresses the problem of providing a technique for improving the flavor of a plant-based oil-in-water emulsion by imparting thereto a rich taste like that of milk.　This method for producing a plant-based oil-in-water emulsion is characterized by comprising all of: (A) a step for preparing at least a raw vegetable protein material, an oil or fat, and a lysophospholipid as raw materials; (B) a step for mixing the raw vegetable protein material and the lysophospholipid in an aqueous system to obtain a liquid mixture; and (C) a step for subsequently mixing the liquid mixture obtained in step (B) and the oil or fat and emulsifying the same to prepare an oil-in-water emulsion.

The invention belongs to the field of biological medicine, and particularly relates to application of LPCAT, phosphatidylcholine and lysophosphatidylcholine as markers in squamous cell carcinoma diagnosis. The ratio of the phosphatidylcholine to the corresponding lysophosphatidylcholine (such as PC (16: 0 / 16: 0) / LPC (16: 0), PC (16: 0 / 20: 4) / LPC (20: 4) and LPCAT1). When the phosphatidylcholine ratio is independently used for diagnosing and distinguishing squamous cell carcinoma, AUC is 0.8015, and certain accuracy is achieved. When the LPCAT1 is used for distinguishing squamous cell carcinoma, AUC is 0.9195, and certain accuracy is achieved. The biomarker provided by the invention can be used for noninvasive diagnosis and distinguishing of squamous-cell carcinoma, overcomes the defects of squamous-cell carcinoma markers, and is expected to replace biopsy.

Provided are: a prophylactic or ameliorating agent for cachexia, which contains a phospholipid and / or lysophospholipid as an active ingredient; and a method for screening a substance for ameliorating cachexia. This prophylactic or ameliorating agent for cachexia is effective not only against cancer cachexia but also against cachexia caused by diseases other than cancer, and is capable of suppressing reduction in skeletal muscle content, suppressing lipoatrophy, and suppressing the expression of inflammatory cytokines.

The invention discloses a krill-based enzymolysis delivery system and a preparation method and application thereof. The preparation method comprises the following steps: mixing krill with water, homogenizing, adjusting the pH value of slurry, adding calcium chloride and dithiothreitol, and stirring to obtain a mixture; adding a compound enzyme, soybean lysophosphatide and chitosan into the mixture, and carrying out an enzymolysis reaction to obtain an enzymolysis mixture; the enzymolysis mixture is cooled and stirred for a period of time, then enzyme deactivation treatment and concentration are performed, and the krill-based enzymolysis delivery system is obtained. According to the preparation method disclosed by the invention, the nutrition of the krill is released to the maximum extent through a strategy of'activation of endogenous enzyme and exogenous enzyme synergism ', and more importantly, lipid and protein components released by the krill in the enzymolysis process are utilized to form a natural'nutrition delivery system' through in-situ self-assembly with an exogenously added specific auxiliary material; therefore, protection, targeted delivery and slow release of the active ingredients are realized, and the nutritional function of the active ingredients in aquatic animals is remarkably improved finally.

The application belongs to the technical field of genetic engineering and protein modification, and specifically provides a lysophospholipase mutant and application thereof. The mutant is a wild-type lysophospholipase with an amino acid sequence of SEQ ID NO: 1, wherein the 128th amino acid is mutated from Cys to Thr, and the specificity of hydrolyzing the 2-position acyl group of phosphatidylcholine is significantly improved. In lysophospholipids generated by hydrolyzing soybean phospholipids by the mutant, the content of sn-1-lysophosphatidylcholine reaches 49.82%-50.26%, and sn-2-lysophosphatidylcholine is almost not generated, and an unexpected technical effect is achieved.